- Conditions
- Multiple Sclerosis
- Interventions
- Cladribine, Placebo, Rebif® new formulation (RNF)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Newport Beach, California • Denver, Colorado + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Cladribine, Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 867 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 17
- States / cities
- Boulder, Colorado • Atlanta, Georgia • Chicago, Illinois + 14 more
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Cladribine
- Drug
- Lead sponsor
- Gregory Wu
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 5
- States / cities
- St Louis, Missouri • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 2 more
- Conditions
- Multiple Sclerosis
- Interventions
- Cladribine, Placebo, Interferon-beta (IFN-beta)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 21
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more
- Conditions
- Multiple Sclerosis
- Interventions
- Cladribine Tablets
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 66
- States / cities
- Cullman, Alabama • Mobile, Alabama • Little Rock, Arkansas + 58 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Gilteritinib 40 MG Oral Tablet, Cladribine, Cytarabine, Filgrastim, Mitoxantrone
- Drug
- Lead sponsor
- Ayman H Qasrawi
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Multiple Sclerosis
- Interventions
- Cladribine Tablets
- Drug
- Lead sponsor
- Keith Edwards, M.D.
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Latham, New York
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
- Conditions
- Multiple Sclerosis (MS)
- Interventions
- Data Collection
- Other
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 662 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 4 more
- Conditions
- Multiple Sclerosis
- Interventions
- Cladribine
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Englewood, Colorado • Fort Collins, Colorado + 14 more
- Conditions
- Multiple Sclerosis
- Interventions
- Cladribine
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Overland Park, Kansas • Dallas, Texas